The global Liposomal-based Drug market was valued at 5537 million in 2024 and is projected to reach US$ 11180 million by 2031, at a CAGR of 10.8% during the forecast period.
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the market\"s potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Liposomal-based Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Liposomal-based Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal-based Drug. This report contains market size and forecasts of Liposomal-based Drug in global, including the following market information:
Global Liposomal-based Drug market revenue, 2020-2025, 2026-2031, ($ millions)
Global top five Liposomal-based Drug companies in 2024 (%)
Total Market by Segment:
Global Liposomal-based Drug market, by Type, 2020-2025, 2026-2031 ($ millions)
Global Liposomal-based Drug market segment percentages, by Type, 2024 (%)
Liposomes Drugs
Lipid Nanoparticle Drugs
Global Liposomal-based Drug market, by Application, 2020-2025, 2026-2031 ($ millions)
Global Liposomal-based Drug market segment percentages, by Application, 2024 (%)
Hospital
Retail Pharmacy
Other
Global Liposomal-based Drug market, by region and country, 2020-2025, 2026-2031 ($ millions)
Global Liposomal-based Drug market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Liposomal-based Drug revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Liposomal-based Drug revenues share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Liposomal-based Drug, market overview.
Chapter 2: Global Liposomal-based Drug market size in revenue.
Chapter 3: Detailed analysis of Liposomal-based Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liposomal-based Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Liposomal-based Drug Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Liposomal-based Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Liposomal-based Drug Overall Market Size
2.1 Global Liposomal-based Drug Market Size: 2024 VS 2031
2.2 Global Liposomal-based Drug Market Size, Prospects & Forecasts: 2020-2031
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Liposomal-based Drug Players in Global Market
3.2 Top Global Liposomal-based Drug Companies Ranked by Revenue
3.3 Global Liposomal-based Drug Revenue by Companies
3.4 Top 3 and Top 5 Liposomal-based Drug Companies in Global Market, by Revenue in 2024
3.5 Global Companies Liposomal-based Drug Product Type
3.6 Tier 1, Tier 2, and Tier 3 Liposomal-based Drug Players in Global Market
3.6.1 List of Global Tier 1 Liposomal-based Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Liposomal-based Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global Liposomal-based Drug Market Size Markets, 2024 & 2031
4.1.2 Liposomes Drugs
4.1.3 Lipid Nanoparticle Drugs
4.2 Segmentation by Type - Global Liposomal-based Drug Revenue & Forecasts
4.2.1 Segmentation by Type - Global Liposomal-based Drug Revenue, 2020-2025
4.2.2 Segmentation by Type - Global Liposomal-based Drug Revenue, 2026-2031
4.2.3 Segmentation by Type - Global Liposomal-based Drug Revenue Market Share, 2020-2031
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global Liposomal-based Drug Market Size, 2024 & 2031
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 Segmentation by Application - Global Liposomal-based Drug Revenue & Forecasts
5.2.1 Segmentation by Application - Global Liposomal-based Drug Revenue, 2020-2025
5.2.2 Segmentation by Application - Global Liposomal-based Drug Revenue, 2026-2031
5.2.3 Segmentation by Application - Global Liposomal-based Drug Revenue Market Share, 2020-2031
6 Sights by Region
6.1 By Region - Global Liposomal-based Drug Market Size, 2024 & 2031
6.2 By Region - Global Liposomal-based Drug Revenue & Forecasts
6.2.1 By Region - Global Liposomal-based Drug Revenue, 2020-2025
6.2.2 By Region - Global Liposomal-based Drug Revenue, 2026-2031
6.2.3 By Region - Global Liposomal-based Drug Revenue Market Share, 2020-2031
6.3 North America
6.3.1 By Country - North America Liposomal-based Drug Revenue, 2020-2031
6.3.2 United States Liposomal-based Drug Market Size, 2020-2031
6.3.3 Canada Liposomal-based Drug Market Size, 2020-2031
6.3.4 Mexico Liposomal-based Drug Market Size, 2020-2031
6.4 Europe
6.4.1 By Country - Europe Liposomal-based Drug Revenue, 2020-2031
6.4.2 Germany Liposomal-based Drug Market Size, 2020-2031
6.4.3 France Liposomal-based Drug Market Size, 2020-2031
6.4.4 U.K. Liposomal-based Drug Market Size, 2020-2031
6.4.5 Italy Liposomal-based Drug Market Size, 2020-2031
6.4.6 Russia Liposomal-based Drug Market Size, 2020-2031
6.4.7 Nordic Countries Liposomal-based Drug Market Size, 2020-2031
6.4.8 Benelux Liposomal-based Drug Market Size, 2020-2031
6.5 Asia
6.5.1 By Region - Asia Liposomal-based Drug Revenue, 2020-2031
6.5.2 China Liposomal-based Drug Market Size, 2020-2031
6.5.3 Japan Liposomal-based Drug Market Size, 2020-2031
6.5.4 South Korea Liposomal-based Drug Market Size, 2020-2031
6.5.5 Southeast Asia Liposomal-based Drug Market Size, 2020-2031
6.5.6 India Liposomal-based Drug Market Size, 2020-2031
6.6 South America
6.6.1 By Country - South America Liposomal-based Drug Revenue, 2020-2031
6.6.2 Brazil Liposomal-based Drug Market Size, 2020-2031
6.6.3 Argentina Liposomal-based Drug Market Size, 2020-2031
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Liposomal-based Drug Revenue, 2020-2031
6.7.2 Turkey Liposomal-based Drug Market Size, 2020-2031
6.7.3 Israel Liposomal-based Drug Market Size, 2020-2031
6.7.4 Saudi Arabia Liposomal-based Drug Market Size, 2020-2031
6.7.5 UAE Liposomal-based Drug Market Size, 2020-2031
7 Companies Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Corporate Summary
7.1.2 Johnson & Johnson Business Overview
7.1.3 Johnson & Johnson Liposomal-based Drug Major Product Offerings
7.1.4 Johnson & Johnson Liposomal-based Drug Revenue in Global Market (2020-2025)
7.1.5 Johnson & Johnson Key News & Latest Developments
7.2 Sun Pharmaceutical
7.2.1 Sun Pharmaceutical Corporate Summary
7.2.2 Sun Pharmaceutical Business Overview
7.2.3 Sun Pharmaceutical Liposomal-based Drug Major Product Offerings
7.2.4 Sun Pharmaceutical Liposomal-based Drug Revenue in Global Market (2020-2025)
7.2.5 Sun Pharmaceutical Key News & Latest Developments
7.3 CSPC
7.3.1 CSPC Corporate Summary
7.3.2 CSPC Business Overview
7.3.3 CSPC Liposomal-based Drug Major Product Offerings
7.3.4 CSPC Liposomal-based Drug Revenue in Global Market (2020-2025)
7.3.5 CSPC Key News & Latest Developments
7.4 Kinyond
7.4.1 Kinyond Corporate Summary
7.4.2 Kinyond Business Overview
7.4.3 Kinyond Liposomal-based Drug Major Product Offerings
7.4.4 Kinyond Liposomal-based Drug Revenue in Global Market (2020-2025)
7.4.5 Kinyond Key News & Latest Developments
7.5 Teva
7.5.1 Teva Corporate Summary
7.5.2 Teva Business Overview
7.5.3 Teva Liposomal-based Drug Major Product Offerings
7.5.4 Teva Liposomal-based Drug Revenue in Global Market (2020-2025)
7.5.5 Teva Key News & Latest Developments
7.6 Fudan-Zhangjiang
7.6.1 Fudan-Zhangjiang Corporate Summary
7.6.2 Fudan-Zhangjiang Business Overview
7.6.3 Fudan-Zhangjiang Liposomal-based Drug Major Product Offerings
7.6.4 Fudan-Zhangjiang Liposomal-based Drug Revenue in Global Market (2020-2025)
7.6.5 Fudan-Zhangjiang Key News & Latest Developments
7.7 Zydus Cadila
7.7.1 Zydus Cadila Corporate Summary
7.7.2 Zydus Cadila Business Overview
7.7.3 Zydus Cadila Liposomal-based Drug Major Product Offerings
7.7.4 Zydus Cadila Liposomal-based Drug Revenue in Global Market (2020-2025)
7.7.5 Zydus Cadila Key News & Latest Developments
7.8 TTY Biopharma
7.8.1 TTY Biopharma Corporate Summary
7.8.2 TTY Biopharma Business Overview
7.8.3 TTY Biopharma Liposomal-based Drug Major Product Offerings
7.8.4 TTY Biopharma Liposomal-based Drug Revenue in Global Market (2020-2025)
7.8.5 TTY Biopharma Key News & Latest Developments
7.9 Pacira
7.9.1 Pacira Corporate Summary
7.9.2 Pacira Business Overview
7.9.3 Pacira Liposomal-based Drug Major Product Offerings
7.9.4 Pacira Liposomal-based Drug Revenue in Global Market (2020-2025)
7.9.5 Pacira Key News & Latest Developments
7.10 Luye Pharma
7.10.1 Luye Pharma Corporate Summary
7.10.2 Luye Pharma Business Overview
7.10.3 Luye Pharma Liposomal-based Drug Major Product Offerings
7.10.4 Luye Pharma Liposomal-based Drug Revenue in Global Market (2020-2025)
7.10.5 Luye Pharma Key News & Latest Developments
7.11 Leadiant Biosciences
7.11.1 Leadiant Biosciences Corporate Summary
7.11.2 Leadiant Biosciences Business Overview
7.11.3 Leadiant Biosciences Liposomal-based Drug Major Product Offerings
7.11.4 Leadiant Biosciences Liposomal-based Drug Revenue in Global Market (2020-2025)
7.11.5 Leadiant Biosciences Key News & Latest Developments
7.12 Ipsen
7.12.1 Ipsen Corporate Summary
7.12.2 Ipsen Business Overview
7.12.3 Ipsen Liposomal-based Drug Major Product Offerings
7.12.4 Ipsen Liposomal-based Drug Revenue in Global Market (2020-2025)
7.12.5 Ipsen Key News & Latest Developments
7.13 Sayre Therapeutics
7.13.1 Sayre Therapeutics Corporate Summary
7.13.2 Sayre Therapeutics Business Overview
7.13.3 Sayre Therapeutics Liposomal-based Drug Major Product Offerings
7.13.4 Sayre Therapeutics Liposomal-based Drug Revenue in Global Market (2020-2025)
7.13.5 Sayre Therapeutics Key News & Latest Developments
7.14 Jazz
7.14.1 Jazz Corporate Summary
7.14.2 Jazz Business Overview
7.14.3 Jazz Liposomal-based Drug Major Product Offerings
7.14.4 Jazz Liposomal-based Drug Revenue in Global Market (2020-2025)
7.14.5 Jazz Key News & Latest Developments
7.15 Alnylam
7.15.1 Alnylam Corporate Summary
7.15.2 Alnylam Business Overview
7.15.3 Alnylam Liposomal-based Drug Major Product Offerings
7.15.4 Alnylam Liposomal-based Drug Revenue in Global Market (2020-2025)
7.15.5 Alnylam Key News & Latest Developments
7.16 Bausch Health
7.16.1 Bausch Health Corporate Summary
7.16.2 Bausch Health Business Overview
7.16.3 Bausch Health Liposomal-based Drug Major Product Offerings
7.16.4 Bausch Health Liposomal-based Drug Revenue in Global Market (2020-2025)
7.16.5 Bausch Health Key News & Latest Developments
7.17 Acrotech Biopharma
7.17.1 Acrotech Biopharma Corporate Summary
7.17.2 Acrotech Biopharma Business Overview
7.17.3 Acrotech Biopharma Liposomal-based Drug Major Product Offerings
7.17.4 Acrotech Biopharma Liposomal-based Drug Revenue in Global Market (2020-2025)
7.17.5 Acrotech Biopharma Key News & Latest Developments
7.18 Takeda
7.18.1 Takeda Corporate Summary
7.18.2 Takeda Business Overview
7.18.3 Takeda Liposomal-based Drug Major Product Offerings
7.18.4 Takeda Liposomal-based Drug Revenue in Global Market (2020-2025)
7.18.5 Takeda Key News & Latest Developments
7.19 Chiesi Farmaceutici
7.19.1 Chiesi Farmaceutici Corporate Summary
7.19.2 Chiesi Farmaceutici Business Overview
7.19.3 Chiesi Farmaceutici Liposomal-based Drug Major Product Offerings
7.19.4 Chiesi Farmaceutici Liposomal-based Drug Revenue in Global Market (2020-2025)
7.19.5 Chiesi Farmaceutici Key News & Latest Developments
7.20 Gilead Sciences
7.20.1 Gilead Sciences Corporate Summary
7.20.2 Gilead Sciences Business Overview
7.20.3 Gilead Sciences Liposomal-based Drug Major Product Offerings
7.20.4 Gilead Sciences Liposomal-based Drug Revenue in Global Market (2020-2025)
7.20.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Liposomal-based Drug Market Opportunities & Trends in Global Market
Table 2. Liposomal-based Drug Market Drivers in Global Market
Table 3. Liposomal-based Drug Market Restraints in Global Market
Table 4. Key Players of Liposomal-based Drug in Global Market
Table 5. Top Liposomal-based Drug Players in Global Market, Ranking by Revenue (2024)
Table 6. Global Liposomal-based Drug Revenue by Companies, (US$, Mn), 2020-2025
Table 7. Global Liposomal-based Drug Revenue Share by Companies, 2020-2025
Table 8. Global Companies Liposomal-based Drug Product Type
Table 9. List of Global Tier 1 Liposomal-based Drug Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Liposomal-based Drug Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segmentation by Type – Global Liposomal-based Drug Revenue, (US$, Mn), 2024 & 2031
Table 12. Segmentation by Type - Global Liposomal-based Drug Revenue (US$, Mn), 2020-2025
Table 13. Segmentation by Type - Global Liposomal-based Drug Revenue (US$, Mn), 2026-2031
Table 14. Segmentation by Application– Global Liposomal-based Drug Revenue, (US$, Mn), 2024 & 2031
Table 15. Segmentation by Application - Global Liposomal-based Drug Revenue, (US$, Mn), 2020-2025
Table 16. Segmentation by Application - Global Liposomal-based Drug Revenue, (US$, Mn), 2026-2031
Table 17. By Region– Global Liposomal-based Drug Revenue, (US$, Mn), 2024 & 2031
Table 18. By Region - Global Liposomal-based Drug Revenue, (US$, Mn), 2020-2025
Table 19. By Region - Global Liposomal-based Drug Revenue, (US$, Mn), 2026-2031
Table 20. By Country - North America Liposomal-based Drug Revenue, (US$, Mn), 2020-2025
Table 21. By Country - North America Liposomal-based Drug Revenue, (US$, Mn), 2026-2031
Table 22. By Country - Europe Liposomal-based Drug Revenue, (US$, Mn), 2020-2025
Table 23. By Country - Europe Liposomal-based Drug Revenue, (US$, Mn), 2026-2031
Table 24. By Region - Asia Liposomal-based Drug Revenue, (US$, Mn), 2020-2025
Table 25. By Region - Asia Liposomal-based Drug Revenue, (US$, Mn), 2026-2031
Table 26. By Country - South America Liposomal-based Drug Revenue, (US$, Mn), 2020-2025
Table 27. By Country - South America Liposomal-based Drug Revenue, (US$, Mn), 2026-2031
Table 28. By Country - Middle East & Africa Liposomal-based Drug Revenue, (US$, Mn), 2020-2025
Table 29. By Country - Middle East & Africa Liposomal-based Drug Revenue, (US$, Mn), 2026-2031
Table 30. Johnson & Johnson Corporate Summary
Table 31. Johnson & Johnson Liposomal-based Drug Product Offerings
Table 32. Johnson & Johnson Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 33. Johnson & Johnson Key News & Latest Developments
Table 34. Sun Pharmaceutical Corporate Summary
Table 35. Sun Pharmaceutical Liposomal-based Drug Product Offerings
Table 36. Sun Pharmaceutical Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 37. Sun Pharmaceutical Key News & Latest Developments
Table 38. CSPC Corporate Summary
Table 39. CSPC Liposomal-based Drug Product Offerings
Table 40. CSPC Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 41. CSPC Key News & Latest Developments
Table 42. Kinyond Corporate Summary
Table 43. Kinyond Liposomal-based Drug Product Offerings
Table 44. Kinyond Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 45. Kinyond Key News & Latest Developments
Table 46. Teva Corporate Summary
Table 47. Teva Liposomal-based Drug Product Offerings
Table 48. Teva Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 49. Teva Key News & Latest Developments
Table 50. Fudan-Zhangjiang Corporate Summary
Table 51. Fudan-Zhangjiang Liposomal-based Drug Product Offerings
Table 52. Fudan-Zhangjiang Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 53. Fudan-Zhangjiang Key News & Latest Developments
Table 54. Zydus Cadila Corporate Summary
Table 55. Zydus Cadila Liposomal-based Drug Product Offerings
Table 56. Zydus Cadila Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 57. Zydus Cadila Key News & Latest Developments
Table 58. TTY Biopharma Corporate Summary
Table 59. TTY Biopharma Liposomal-based Drug Product Offerings
Table 60. TTY Biopharma Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 61. TTY Biopharma Key News & Latest Developments
Table 62. Pacira Corporate Summary
Table 63. Pacira Liposomal-based Drug Product Offerings
Table 64. Pacira Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 65. Pacira Key News & Latest Developments
Table 66. Luye Pharma Corporate Summary
Table 67. Luye Pharma Liposomal-based Drug Product Offerings
Table 68. Luye Pharma Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 69. Luye Pharma Key News & Latest Developments
Table 70. Leadiant Biosciences Corporate Summary
Table 71. Leadiant Biosciences Liposomal-based Drug Product Offerings
Table 72. Leadiant Biosciences Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 73. Leadiant Biosciences Key News & Latest Developments
Table 74. Ipsen Corporate Summary
Table 75. Ipsen Liposomal-based Drug Product Offerings
Table 76. Ipsen Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 77. Ipsen Key News & Latest Developments
Table 78. Sayre Therapeutics Corporate Summary
Table 79. Sayre Therapeutics Liposomal-based Drug Product Offerings
Table 80. Sayre Therapeutics Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 81. Sayre Therapeutics Key News & Latest Developments
Table 82. Jazz Corporate Summary
Table 83. Jazz Liposomal-based Drug Product Offerings
Table 84. Jazz Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 85. Jazz Key News & Latest Developments
Table 86. Alnylam Corporate Summary
Table 87. Alnylam Liposomal-based Drug Product Offerings
Table 88. Alnylam Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 89. Alnylam Key News & Latest Developments
Table 90. Bausch Health Corporate Summary
Table 91. Bausch Health Liposomal-based Drug Product Offerings
Table 92. Bausch Health Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 93. Bausch Health Key News & Latest Developments
Table 94. Acrotech Biopharma Corporate Summary
Table 95. Acrotech Biopharma Liposomal-based Drug Product Offerings
Table 96. Acrotech Biopharma Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 97. Acrotech Biopharma Key News & Latest Developments
Table 98. Takeda Corporate Summary
Table 99. Takeda Liposomal-based Drug Product Offerings
Table 100. Takeda Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 101. Takeda Key News & Latest Developments
Table 102. Chiesi Farmaceutici Corporate Summary
Table 103. Chiesi Farmaceutici Liposomal-based Drug Product Offerings
Table 104. Chiesi Farmaceutici Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 105. Chiesi Farmaceutici Key News & Latest Developments
Table 106. Gilead Sciences Corporate Summary
Table 107. Gilead Sciences Liposomal-based Drug Product Offerings
Table 108. Gilead Sciences Liposomal-based Drug Revenue (US$, Mn) & (2020-2025)
Table 109. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Liposomal-based Drug Product Picture
Figure 2. Liposomal-based Drug Segment by Type in 2024
Figure 3. Liposomal-based Drug Segment by Application in 2024
Figure 4. Global Liposomal-based Drug Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Liposomal-based Drug Market Size: 2024 VS 2031 (US$, Mn)
Figure 7. Global Liposomal-based Drug Revenue: 2020-2031 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by Liposomal-based Drug Revenue in 2024
Figure 9. Segmentation by Type – Global Liposomal-based Drug Revenue, (US$, Mn), 2024 & 2031
Figure 10. Segmentation by Type - Global Liposomal-based Drug Revenue Market Share, 2020-2031
Figure 11. Segmentation by Application – Global Liposomal-based Drug Revenue, (US$, Mn), 2024 & 2031
Figure 12. Segmentation by Application - Global Liposomal-based Drug Revenue Market Share, 2020-2031
Figure 13. By Region - Global Liposomal-based Drug Revenue Market Share, 2020-2031
Figure 14. By Country - North America Liposomal-based Drug Revenue Market Share, 2020-2031
Figure 15. United States Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 16. Canada Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 17. Mexico Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 18. By Country - Europe Liposomal-based Drug Revenue Market Share, 2020-2031
Figure 19. Germany Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 20. France Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 21. U.K. Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 22. Italy Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 23. Russia Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 24. Nordic Countries Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 25. Benelux Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 26. By Region - Asia Liposomal-based Drug Revenue Market Share, 2020-2031
Figure 27. China Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 28. Japan Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 29. South Korea Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 30. Southeast Asia Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 31. India Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 32. By Country - South America Liposomal-based Drug Revenue Market Share, 2020-2031
Figure 33. Brazil Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 34. Argentina Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 35. By Country - Middle East & Africa Liposomal-based Drug Revenue Market Share, 2020-2031
Figure 36. Turkey Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 37. Israel Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 38. Saudi Arabia Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 39. UAE Liposomal-based Drug Revenue, (US$, Mn), 2020-2031
Figure 40. Johnson & Johnson Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 41. Sun Pharmaceutical Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 42. CSPC Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 43. Kinyond Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 44. Teva Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 45. Fudan-Zhangjiang Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 46. Zydus Cadila Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 47. TTY Biopharma Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 48. Pacira Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 49. Luye Pharma Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 50. Leadiant Biosciences Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 51. Ipsen Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 52. Sayre Therapeutics Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 53. Jazz Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 54. Alnylam Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 55. Bausch Health Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 56. Acrotech Biopharma Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 57. Takeda Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 58. Chiesi Farmaceutici Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 59. Gilead Sciences Liposomal-based Drug Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
